

Parent  
100848.213102US4

### Interview

During an interview with applicant's attorney, Robert D. Fish on February 4, 2003, the primary examiner, Howard Owens, and the supervisory examiner, James O. Wilson, confirmed the allowability of claims 2, 4, and 6-10, provided those claims were amended to include all the limitations of the corresponding parent claims. The present supplemental response to office action accomplishes just that.

The examiners indicated that revised claims 1, 3, and 5 were still invalid under statutory double patenting as being drawn to the same invention as previously issued claims. Claims 1, 3, and 5 are canceled herein.

The examiners indicated that they would evaluate whether claims 11-13 should be addressed in this case, or whether they will require the applicant to file a divisional to address those claims.

Claims 14-16 are canceled herein.

### **REQUEST FOR ALLOWANCE**

Claims 2, 4, and 6-13 are pending in this application. The applicant requests allowance of all pending claims.

Respectfully submitted,  
Rutan & Tucker, LLP

Dated: \_\_\_\_\_

By: \_\_\_\_\_  
Robert D. Fish  
Reg. No. 33,880

Attorneys for Applicant(s)  
611 Anton Blvd., Fourteenth Floor  
Costa Mesa, CA 92626  
Tel.: (714) 641-5100  
Fax: (714) 546-9035

Patent  
100848.213102US4

A list of the claims amended or added herein, identifying the amendments entered herein, is set forth below.

1. Canceled
2. (Amended) A method of modulating Type 1 and Type 2 response in activated T cells of a human patient comprising administering ribavirin to the T cells in a dosage to promote the Type 1 response and suppress the Type 2 response, [The method of claim 1] wherein the amount of ribavirin added provides a concentration of about 0.25 - 6.7  $\mu\text{g/ml}$  in a medium supporting the lymphocytes.
3. Canceled.
4. (Amended) A method of treating a patient having a disease which includes a viral component and a non-viral component, the non-viral component being characterized by reduced Type 1 levels and increased Type 2 levels in activated T-lymphocytes, comprising administering ribavirin to the patient under a protocol intended to promote the Type 1 response and suppress the Type 2 response, and [The method of claim 3 further comprising] adding interferon alpha to the lymphocytes.
5. Canceled.
6. (Amended) A method of inhibiting a virus by growing a virus in an environment having lymphocytes which produce Type 1 and Type 2 cytokine responses, and adding ribavirin to the environment in a concentration for the purpose of increasing the Type 1 response and suppressing the Type 2 response, [The method of claim 5] wherein the virus comprises Hepatitis C.
7. (Amended) The method of claim [5] 6 wherein the environment comprises a liver.
8. (Amended) The method of claim [5] 6 wherein the environment comprises hepatocytes.
14. Canceled.

Patent  
100848.213102US4

15. Canceled.

16. Canceled.